Cardinal Health Inc Stock Price, News & Analysis

Cardinal Health reported Q3 FY22 revenues of $44.8 billion, a 14% increase from last year. However, the company faced a GAAP operating loss of $97 million, mainly due to a $474 million non-cash goodwill impairment in the Medical segment. Non-GAAP operating earnings fell 21% to $545 million, while non-GAAP diluted EPS decreased 5% to $1.45. The company finalized an opioid settlement costing up to $6 billion over 18 years. FY22 guidance was adjusted, projecting non-GAAP EPS of $5.15 to $5.25 and Medical segment profit decline of 45-55%.

AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have settled opioid-related claims with the Washington Attorney General, agreeing to pay up to $518 million. This payment resolves lawsuits filed by the state and its subdivisions, allowing for the dismissal of ongoing litigation. The settlement aligns with a previously announced agreement effective April 2, 2022, aimed at addressing a significant portion of opioid claims against the distributors. The companies dispute the allegations but see this as steps toward broader resolutions and relief for impacted communities.

Cardinal Health (NYSE: CAH) will release its third-quarter financial results for fiscal year 2022 on May 5 prior to market opening. A webcast discussing these results will start at 8:30 a.m. Eastern. Investors can access the webcast and slides via the company’s Investor Relations page without an access code. Cardinal Health is a global distributor of pharmaceuticals and medical products, operating in over 30 countries with approximately 44,000 employees.

Cardinal Health (CAH) announced plans to construct a 574,670 square foot medical distribution center in Columbus, Ohio, expected to be operational by late 2022 or early 2023. This facility aims to enhance safety, service quality, and operational efficiencies while accommodating fluctuations in volume and labor. The new center will replace an existing 235,000 square foot facility in Obetz and create new job opportunities in the Ohio Valley. The project is supported by a partnership with Duke Realty and is part of a broader strategy to expand U.S. warehouse capacity, ensuring better logistic support.

Cardinal Health (CAH) has launched the first surgical incise drape featuring patented BeneHold™ CHG adhesive technology, designed to reduce surgical site contamination risks. This unique drape utilizes Chlorhexidine Gluconate (CHG), an antiseptic trusted for skin preparation, to enhance patient care. Surgical site infections (SSIs), responsible for 20% of hospital-acquired infections and associated with significant costs of over $3.3 billion annually, can be mitigated by this innovative product. The drape meets FDA requirements and has shown promising results in studies against MRSA contamination.

Settlement Announcement: AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have reached an agreement to settle the majority of opioid lawsuits with participation from 46 of 49 eligible states and over 90% of litigating political subdivisions. The settlement totals approximately $19.5 billion to be distributed over 18 years, with individual contributions of $6.1 billion, $6.0 billion, and $7.4 billion from AmerisourceBergen, Cardinal Health, and McKesson, respectively. The agreement aims to provide relief to communities affected by the opioid crisis.

Cue Health Inc. (Nasdaq: HLTH) has partnered with Cardinal Health (NYSE: CAH) to expand distribution of its COVID-19 tests across traditional and non-traditional healthcare settings. This collaboration aims to enhance the availability of Cue's nucleic acid amplification tests, which have shown 97.8% concordance with PCR tests, and the innovative at-home test, the first of its kind to gain Emergency Use Authorization from the FDA. Both professional and OTC/home test kits will be available, supporting healthcare providers’ evolving diagnostic needs.